Brian Evans

New Study Reinforces The Contribution Of S6K1 Kinase In Obesity And Aging

ArticlePress release
Current Medical News
Diabetes Care
Contributed byKrish Tangella MD, MBAFeb 28, 2017

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and Barcelona University (UB) Dr. George Thomas, head of the Metabolism and Cancer research group, and Dr. Sara Kozma, are reporting in Nature this week, on the role of S6K1 in re-directing glutamyl-prolyl tRNA synthetase (EPRS) from inhibition of translation to transport fatty acids. The study was carried out in collaboration with researchers from Cleveland Clinic and Illinois University, and could potentially lead to the development of biomarkers and targeted therapies against obesity and aging.

Previous studies by Drs. Thomas and Kozma had shown that S6K1 plays a critical role in fat tissue expansion by transcriptionally regulating the differentiation of mesenchymal stem cells (MSCs) into adipocytes (fat cells). As Dr. Thomas explained "In the meantime, Paul Fox contacted us proposing a possible connection between S6K1 and the glutamyl-prolyl-tRNA snythetase (EPRS), together we found that that S6K1 phosphorylation is required to release EPRS from its canonical role in protein synthesis to form the interferon γ inhibitor of translation (GAIT) complex, which blocks the translation of interferon regulated genes."

"This change of function is key, since we also found that EPRS mediates the localization of the fatty acid transport protein 1 (FATP1) to the membrane, stimulating the uptake of long chain fatty acids," adds Dr. Kozma. "This confirmed a dual role of S6K1 in contributing to adiposity and aging. Indeed, mice with phospho-deficient EPRS present the same physical characteristics (phenotype) as S6K1-deficient mice: low body weight, reduced adipose tissue mass, and increased lifespan. These results reinforce the concept that S6K1 may serve as a predictor of obesity or as a drug target to suppress obesity."

Dr. Kozma is currently collaborating with Dr. José Manuel Fernández-Real of the CIBERobn research group at the Hospital of Girona "Josep Trueta" and IDIBGI, in a project funded by La Marató de TV3 to obtain fat tissue samples to validate these results in humans and develop new biomarkers of adipose tissue expansion.


Materials provided by IDIBELL-Bellvitge Biomedical Research InstituteNote: Content may be edited for style and length.

Disclaimer: DoveMed is not responsible for the accuracy of the adapted version of news releases posted to DoveMed by contributing universities and institutions.

Primary Resource:

Arif, A., Terenzi, F., Potdar, A. A., Jia, J., Sacks, J., China, A., ... & Chen, J. (2017). EPRS is a critical mTORC1–S6K1 effector that influences adiposity in mice. Nature. DOI: 10.1038/nature21380

Was this article helpful

On the Article

Krish Tangella MD, MBA picture
Approved by

Krish Tangella MD, MBA

Pathology, Medical Editorial Board, DoveMed Team

0 Comments

Please log in to post a comment.

Related Articles

Test Your Knowledge

Asked by users

Related Centers

Loading

Related Specialties

Loading card

Related Physicians

Related Procedures

Related Resources

Join DoveHubs

and connect with fellow professionals

Related Directories

Who we are

At DoveMed, our utmost priority is your well-being. We are an online medical resource dedicated to providing you with accurate and up-to-date information on a wide range of medical topics. But we're more than just an information hub - we genuinely care about your health journey. That's why we offer a variety of products tailored for both healthcare consumers and professionals, because we believe in empowering everyone involved in the care process.
Our mission is to create a user-friendly healthcare technology portal that helps you make better decisions about your overall health and well-being. We understand that navigating the complexities of healthcare can be overwhelming, so we strive to be a reliable and compassionate companion on your path to wellness.
As an impartial and trusted online resource, we connect healthcare seekers, physicians, and hospitals in a marketplace that promotes a higher quality, easy-to-use healthcare experience. You can trust that our content is unbiased and impartial, as it is trusted by physicians, researchers, and university professors around the globe. Importantly, we are not influenced or owned by any pharmaceutical, medical, or media companies. At DoveMed, we are a group of passionate individuals who deeply care about improving health and wellness for people everywhere. Your well-being is at the heart of everything we do.

© 2023 DoveMed. All rights reserved. It is not the intention of DoveMed to provide specific medical advice. DoveMed urges its users to consult a qualified healthcare professional for diagnosis and answers to their personal medical questions. Always call 911 (or your local emergency number) if you have a medical emergency!